QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Dulaglutide??
Dulaglutide (LY2189265, CAS 923950-08-7) is a long-acting GLP-1 receptor agonist consisting of two modified GLP-1 analogue peptides covalently linked via a small peptide linker to an Fc region of human IgG4 — creating a homodimeric fusion protein of ~63 kDa. The GLP-1 moiety is 90% homologous to native GLP-1(7-37) with two amino acid substitutions (Ala⁸→Aib, Gly²²→Glu) that confer DPP-IV resistance. The IgG4 Fc extends half-life to approximately 5 days, enabling weekly dosing in clinical use (Trulicity®). Dulaglutide activates GLP-1R (Gs/cAMP/PKA) — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central GLP-1R.
Research Applications
GLP-1R Signalling
Gs/cAMP/PKA/Epac2 pathway, GLP-1R-dependent β-cell cAMP dynamics, receptor internalisation kinetics
β-Cell Biology
Glucose-stimulated insulin secretion (GSIS), β-cell proliferation/survival, PDX-1 expression
Glucagon Suppression
α-cell GLP-1R-mediated glucagon inhibition, hepatic glucose output reduction, hypoglycaemia risk
Obesity & CNS Appetite
Hypothalamic GLP-1R feeding suppression, gastric emptying delay, adipose lipolysis changes
Cardioprotection
GLP-1R cardioprotective signalling, atherosclerosis models, CV outcome comparison vs. other GLP-1RAs
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 923950-08-7 |
| Also Known As | LY2189265, Trulicity® active peptide |
| Molecular Weight | ~63 kDa (IgG4-Fc homodimer) |
| Half-Life | ~5 days (IgG4-Fc mediated) |
| Peptide Type | Long-acting GLP-1R agonist Fc-fusion protein |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |
